Celldex Therapeutics (CLDX) - FREE Research Report

Catlin Avery W who is Sr. VP & CFO at CELLDEX THERAPT bought 500 shares at $5.95 per share for a total value of $2,975.00 on July 1, 2013. Following this transaction, the Sr. VP & CFO owned 14,109 shares meaning that the stake was boosted by 3.67% with the 500 share acquisition.

Marucci Anthony S who is President & CEO at CELLDEX THERAPT bought 500 shares at $5.95 per share for a total value of $2,975.00 on July 1, 2013. Following this transaction, the President & CEO owned 43,368 shares meaning that the stake was boosted by 1.17% with the 500 share acquisition.

The shares most recently traded at $20.74, up $2.09, or 11.21% since the insider transactions.

The average volume for Celldex Therapeutics has been 1.6 million shares per day over the past 30 days. Celldex Therapeutics has a market cap of $1.5 billion and is part of the health care sector and drugs industry. Shares are up 177.94% year to date as of the close of trading on Wednesday.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Currently there are 7 analysts that rate Celldex Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CLDX - FREE

TheStreet Quant Ratings rates Celldex Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and deteriorating net income. Get the full Celldex Therapeutics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

Let's Get Real About Abercrombie & Fitch

Amazon Can't Even Be Stopped By a Massive Hurricane

Play Defense, Play the Dollar: Cramer's 'Mad Money' Recap (Tuesday 8/29/17)

Jackson Hole and a Solar Eclipse -- Week in Review